Patient Initials [ ][ ][ ]

SAE: CHAIN PB-SAM PB-SAM Number [2][0] [ ][ ][ ]

## Serious Adverse Event - A

		1. SAE INITIAL DETAILS	
1.1.	DATE of SAE onset	<u> </u>	
1.2.	DATE child seen or information received by research team	/// D D/M M/ Y Y Y Y	
1.3.	<b>Classification at</b> <b>presentation</b> When the study team first became aware of the SAE. Tick the highest <u>one</u> applicable	<ul> <li>Death</li> <li>Readmission to study hospital</li> <li>Readmission is indicated but parent/carer declines admission</li> <li>Life-threatening event</li> <li>Persistent or significant disability/incapacity</li> <li>Event that prolongs hospitalisation whilst already in hospital (deterioration)</li> <li>Other serious medical event where medical intervention was required e.g. new diagnosis of TB, sickle cell disease</li> </ul>	
1.4.	<b>Reported by</b> (Tick one)	<ul> <li>Parent/caregiver</li> <li>Health Professional</li> <li>From medical records or discharge letter</li> </ul>	
1.5.	On study drugs at the onset of the SAE? (tick all that apply)	□ None □ Pancreatic enzymes/Placebo □ Urso/Placebo	
1.6.	Any other medication in the last 7 days prior to onset of SAE? (tick all that apply) Give details with specific medications used in the text box below (section 1.07)	No medication         Antibiotics       Antimalarial         IV fluids       Blood Transfusion         Anticonvulsants       Anti-TB         ART       Traditional or Herbal         Co-trimoxazole       Yes, but unknown         Other	
1.7.		the SAE, where and when did it occur, was there any relation to timing of study drug dure, or relation to any other medication, who was involved? Describe any background factors or contributed to the SAE event	

Patient Initials [ ][ ][ ]

# N PB-SAM PB-SAM Number [2][0][][]]

1.8.	Describe the <u>new</u> clinical features of this SAE event (describe clinical findings from examination, medical records,
_	or from caregiver)
1.9.	Describe any investigations or changes to lab results <u>RELEVANT</u> to this SAE event for its diagnosis or
	management* (i.e. Were there investigations done to investigate this SAE? The text needs to be sufficient to
	enable an independent reviewer to assess severity, type of illness and whether there is relationship to study
	drugs/medications)
1.10.	Describe the initial treatment given or other actions taken for this SAE*
1.10.	
1.11.	Describe the response to initial treatment *
1.12.	Describe any further clinical investigations and clinical progress*
	* write N/A if not applicable (e.g. death in the community)
1.13.	Suspected initial diagnosis for the cause of the SAE (e.g. pneumonia, sepsis etc)

Patient Initials [ ][ ][ ]



	2.0 Additional Docume	entation
2.1	Is there any additional documentation for this SAE	□ YES □ NO
2.2	If Yes, select all that apply	Clinical notes
	(Make copies of selected documents, certify and attach to the	□ Lab results
	SAE CRF)	□ X ray
		Death certificate
		Discharge summary
		□ Other, Specify

			3.0 PART A CRF COMPLETION
3.1	a)	CRF Completed by (Initials) – to be signed when complete. Do not sign if any fields are empty	
	b)	Date	
	c)	Time	: 24 h clock

3.2.	a)	CRF Reviewed by (Initials)	
	b)	Date	$\frac{1}{D} \frac{1}{M} \frac{1}{M} \frac{1}{Y} \frac{1}$
	c)	Time	: 24 h clock

## SAE: CHAIN PB-SAM PB-SAM Number [2][0] [ ][ ][ ]

## **Serious Adverse Event - B**

	4.0 SAE FINAL DETAILS
4.1	<b>Circumstances</b> : What was the SAE, where and when did it occur, was there any relation to timing of study drug administration or other procedure, or relation to any other medication, who was involved? Describe any background factors or co-morbidities that may have contributed to the SAE event
4.2	Describe the additional clinical features of this SAE event (describe clinical findings from examination, medical records, or from caregiver)
4.3	Describe any investigations or changes to results <u>RELEVANT</u> to this SAE event for its diagnosis or management* ( <i>i.e.</i> Were there investigations done to investigate this SAE? The text needs to be sufficient to enable an independent reviewer to assess severity, type of illness and whether there is relationship to study drugs/medications)
4.4	Describe the treatment given or other actions taken for this SAE*
4.5	<b>Describe the response to treatment, any further clinical investigations and clinical progress*</b> * write N/A if not applicable (e.g. death in the community)

 SAE: CHAIN PB-SAM
 ΛΛΤΑΑΤΛΛ

 PB-SAM Number [2][0] [ ][ ][ ]

\*\*\*\*\*\*

#### Patient Initials [ ][ ][ ]

	5.0 SAE CLASSIFICATION		
5.1	End date (dd/mm/yyyy)	<pre>// or if no end date (died, or recovered) D D/M M/ Y Y Y Y On-going &amp; receiving care Unknown</pre>	
5.2	<b>Final Classification</b> Tick the highest <u>one</u> applicable	<ul> <li>Death</li> <li>Readmission to study hospital</li> <li>Readmission is indicated but parent/carer declines admission</li> <li>Life-threatening event</li> </ul>	
	Was this event a suspected	unexpected serious adverse reaction (SUSAR)?	

	6.0 RELATIONSHIP OF EVENT TO STUDY DRUGS	
6.1	No temporal relationship to drug; <b>and</b> alternate aetiology (clinical state, environmental or other interventions); <b>and</b> does not follow known pattern of response to study product	☐ No Relationship
	Unlikely temporal relationship to drug; <b>and</b> alternate aetiology likely (clinical state, environmental or other interventions); <b>and</b> does not follow known typical or plausible pattern of response to drug.	Unlikely
	Reasonable temporal relationship to drug; or event not readily produced by clinical state, environmental or other interventions; or similar pattern of response to that seen with other drugs	Possible
	Reasonable temporal relationship to drug; and event not readily produced by clinical state, environment, or other interventions or known pattern of response seen with other drugs	Probable
	Reasonable temporal relationship to drug; and event not readily produced by clinical state, environment, or other interventions; and known pattern of response seen with study drugs	Definite

Patient Initials [ ][ ][ ]

# <sup>N PB-SAM</sup> РВ-SAM Number [2][0] [ ][ ]

7.1	diagnosis should be based on examination General	Anaemia	□ Sickle Cell Disease	□ Thalassaemia
		□ Renal impairment	□ Ileus	Nephritis
		□ Liver dysfunction	□ Nephrotic syndrome	
		□ Congenital cardiac dise	ease confirmed by echo	
7.2	Respiratory	□ LRTI/pneumonia	□ Bronchiolitis	
		Pulmonary TB		
		Otitis media	🗆 Asthma 🛛 Asp	piration e.g. of feed
7.3	Infection	Gastroenteritis Malaria	Sepsis	Confirmed
		Extra pulmonary TB	Soft tissue infectio	n 🗆 UTI
		HIV related illness	<ul> <li>Measles</li> </ul>	□ Varicella
		□ Osteomyelitis	Febrile illness unsp	ecified
		Confirmed enteric feve	r 🛛 Typhoid/paratypho	oid with perforation
7.4	CNS	Febrile convulsions	Epilepsy	
		Other encephalopathy	<i>i i</i>	Cerebral palsy
		Probable meningitis		ningitis
		LP confirmed meningiti	S	
		Confirmed diagnosis contraction	ongenital syndrome	
7.5	Other confirmed diagnosis	□ Failed appetite test only/severe malnutrition only (readmission).		
		Suspected drug toxicity	<b>y</b> (if due to study drug, comp	lete toxicity CRF)
		Other known diagnosis	5:	

	8.0 Additional Docum	entation
8.1	Is there any additional documentation for this SAE	□ YES □ NO
8.2	If Yes, select all that apply	<ul> <li>Clinical notes</li> <li>Lab results</li> </ul>
	(Make copies of selected documents, certify and attach to the SAE CRF)	□ X ray
		Death certificate
		Discharge summary
		□ Other, Specify

#### Patient Initials [ ][ ][ ]



PB-SAM Number [2][0] [ ][ ][ ]

			9.0 Part B CRF Completion
9.1	a)	CRF Completed by (Initials) – to be signed when complete. Do not sign if any fields are empty	
	b)	Date	$\frac{1}{D} \frac{1}{D/M} \frac{1}{M/Y} \frac{1}{Y} $
	c)	Time	: 24 h clock

9.2	a) CRF Reviewed by (Initials)	
	b) <b>Date</b>	$\frac{1}{D} \frac{1}{D/M} \frac{1}{M/Y} \frac{1}{Y} $
	c) <b>Time</b>	: 24 h clock

Additional notes (Not for entry into database) all entries should be initialled and dated

#### Patient Initials [ ][ ][ ]



END of SAE CRF